# Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Canonical URL: https://biopharmsignal.com/news/IMRX/immuneering-announces-exceptional-64-overall-survival-at-12-months-in-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp
Ticker: IMRX
Company: Immuneering
Source: Immuneering
Published: 2026-01-07 21:00 EST
Original Source URL: https://ir.immuneering.com
## Summary

- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall

## Article Body
- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall
## Recent Company News
- 2026-06-01 11:30 EST — [Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO](https://biopharmsignal.com/news/IMRX/immuneering-presents-compelling-17-3-month-median-overall-survival-and-favorable-tolerability-with-atebimetinib-chemotherapy-in-first-line-pancreatic-cancer-patients-at-asco) — Source: Immuneering
- 2026-05-21 21:00 EST — [Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy](https://biopharmsignal.com/news/IMRX/immuneering-reports-17-3-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus-chemotherapy) — Source: Immuneering
- 2026-05-15 11:35 EST — [Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/IMRX/immuneering-reports-first-quarter-2026-financial-results-and-provides-business-updates) — Source: Immuneering
- 2026-04-21 20:05 EST — [Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/IMRX/immuneering-to-present-new-survival-data-from-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp-in-an-oral-presentation-at-the-2026-asco-annual-meeting) — Source: Immuneering
- 2026-04-20 13:00 EST — [Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond](https://biopharmsignal.com/news/IMRX/immuneering-presents-genetic-data-at-aacr-annual-meeting-demonstrating-mechanism-to-improve-durability-and-survival-supporting-use-of-atebimetinib-in-first-line-pancreatic-cancer-and-beyond) — Source: Immuneering
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)